Article (Scientific journals)
In silico regenerative medicine: how computational tools allow regulatory and financial challenges to be addressed in a volatile market.
Geris, Liesbet; Guyot, Y.; Schrooten, J. et al.
2016In Interface Focus, 6 (2), p. 20150105
Peer Reviewed verified by ORBi
 

Files


Full Text
ACTBIO_Combining microCT-based characterization with empirical modelling as a robust screen.pdf
Publisher postprint (3.54 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
bioprocess; bioreactor; in silico model; regenerative medicine; tissue engineering
Abstract :
[en] The cell therapy market is a highly volatile one, due to the use of disruptive technologies, the current economic situation and the small size of the market. In such a market, companies as well as academic research institutes are in need of tools to advance their understanding and, at the same time, reduce their R&D costs, increase product quality and productivity, and reduce the time to market. An additional difficulty is the regulatory path that needs to be followed, which is challenging in the case of cell-based therapeutic products and should rely on the implementation of quality by design (QbD) principles. In silico modelling is a tool that allows the above-mentioned challenges to be addressed in the field of regenerative medicine. This review discusses such in silico models and focuses more specifically on the bioprocess. Three (clusters of) examples related to this subject are discussed. The first example comes from the pharmaceutical engineering field where QbD principles and their implementation through the use of in silico models are both a regulatory and economic necessity. The second example is related to the production of red blood cells. The described in silico model is mainly used to investigate the manufacturing process of the cell-therapeutic product, and pays special attention to the economic viability of the process. Finally, we describe the set-up of a model capturing essential events in the development of a tissue-engineered combination product in the context of bone tissue engineering. For each of the examples, a short introduction to some economic aspects is given, followed by a description of the in silico tool or tools that have been developed to allow the implementation of QbD principles and optimal design.
Disciplines :
Engineering, computing & technology: Multidisciplinary, general & others
Author, co-author :
Geris, Liesbet  ;  Université de Liège > Département d'aérospatiale et mécanique > Génie biomécanique
Guyot, Y.
Schrooten, J.
Papantoniou, I.
Language :
English
Title :
In silico regenerative medicine: how computational tools allow regulatory and financial challenges to be addressed in a volatile market.
Publication date :
2016
Journal title :
Interface Focus
ISSN :
2042-8898
eISSN :
2042-8901
Publisher :
The Royal Society, London, United Kingdom
Volume :
6
Issue :
2
Pages :
20150105
Peer reviewed :
Peer Reviewed verified by ORBi
European Projects :
FP7 - 279100 - BRIDGE - Biomimetic process design for tissue regeneration: from bench to bedside via in silico modelling
Funders :
CE - Commission Européenne [BE]
Available on ORBi :
since 11 July 2016

Statistics


Number of views
54 (6 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
18
Scopus citations®
without self-citations
17
OpenCitations
 
14

Bibliography


Similar publications



Contact ORBi